BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Moodys
UBS
Accenture
McKesson
Mallinckrodt
Novartis
Queensland Health
Farmers Insurance

Generated: January 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,510,383

« Back to Dashboard

Summary for Patent: 5,510,383
Title: Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
Abstract:Disclosed is the use of cloprostenol, fluprostenol, and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
Inventor(s): Bishop; John E. (Arlington, TX), DeSantis, Jr.; Louis (Fort Worth, TX), Sallee; Verney L. (Burleson, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:08/101,598
Patent Claims: 1. A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula: ##STR9## wherein: R.sup.1 =hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C.sub.1 -C.sub.12 alkyl, cycloalkyl or aryl; and R.sup.2 =Cl or CF.sub.3.

2. The method of claim 1, wherein R.sup.1 is selected from the group consisting of H, CH.sub.3, CH(CH.sub.3).sub.2 and C(CH.sub.3).sub.3.

3. The method of claim 1, wherein R.sup.1 is selected from the group consisting of Na.sup.+ and CH.sub.3 N.sup.+ (CH.sub.2 OH).sub.3.

4. The method of claim 1, wherein R.sup.2 is Cl.

5. The method of claim 1, wherein R.sup.2 is CF.sub.3.

6. The method of claim 1, wherein between about 0.001 and about 1000 .mu.g/eye of a compound of formula (I) is administered.

7. The method of claim 6, wherein between about 0.01 and about 100 .mu.g/eye of a compound of formula (I) is administered.

8. The method of claim 6, wherein between about 0,05 and about 10 .mu.g/eye of a compound of formula (I) is administered.

9. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising a therapeutically effective amount of a compound of formula: ##STR10## wherein: R.sup.1 =hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C.sub.1 -C.sub.12 alkyl, cycloalky or aryl; and R.sup.2 =Cl or CF.sub.3.

10. The composition of claim 9, wherein R.sup.1 is selected from the group consisting of H, CH.sub.3, CH(CH.sub.3).sub.2 and C(CH.sub.3).sub.3.

11. The composition of claim 9, wherein R.sup.1 is selected from the group consisting of Na.sup.+ and CH.sub.3 N.sup.+ (CH.sub.2 OH).sub.3.

12. The composition of claim 9, wherein R.sup.2 is Cl.

13. The composition of claim 9, wherein R.sup.2 is CF.sub.3.

14. The composition of claim 9, wherein between about 0.001 and about 100 .mu.g/eye of a compound of formula (I) is administered.

15. The composition of claim 14, wherein between about 0.01 and about 100 .mu.g/eye of a compound of formula (I) is administered.

16. The composition of claim 15, wherein between about 0.05 and about 10 .mu.g/eye of a compound of formula (I) is administered.

17. A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula: ##STR11## wherein: R.sup.1 =a pharmaceutically acceptable ester moiety; and R.sup.2 =Cl or CF.sub.3.

18. The method of claim 17, wherein R.sup.2 is Cl.

19. The method of claim 17, wherein R.sup.2 is CF.sub.3.

20. The method of claim 17, wherein between about 0.001 and about 1000 .mu.g eye of a compound of formula (I) is administered.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
QuintilesIMS
McKesson
Chubb
Federal Trade Commission
Chinese Patent Office
Harvard Business School
Cipla
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot